Cargando…

Calcium phosphate ceramics as bone graft substitutes in filling bone tumor defects

BACKGROUND: Synthetic bio-inert materials are currently used as an alternative to autogenous bone graft. Calcium hydroxyapatite (HA) and Beta tri-calcium phosphate (β-TCP), which belong to the calcium phosphate ceramics group, are biocompatible and osteo-conductive. The purpose of this study is to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Saikia, KC, Bhattacharya, TD, Bhuyan, SK, Talukdar, DJ, Saikia, SP, Jitesh, P
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759621/
https://www.ncbi.nlm.nih.gov/pubmed/19826522
http://dx.doi.org/10.4103/0019-5413.39588
_version_ 1782172693216362496
author Saikia, KC
Bhattacharya, TD
Bhuyan, SK
Talukdar, DJ
Saikia, SP
Jitesh, P
author_facet Saikia, KC
Bhattacharya, TD
Bhuyan, SK
Talukdar, DJ
Saikia, SP
Jitesh, P
author_sort Saikia, KC
collection PubMed
description BACKGROUND: Synthetic bio-inert materials are currently used as an alternative to autogenous bone graft. Calcium hydroxyapatite (HA) and Beta tri-calcium phosphate (β-TCP), which belong to the calcium phosphate ceramics group, are biocompatible and osteo-conductive. The purpose of this study is to analyse the use of HA and β-TCP in their ceramic forms as a bone graft substitute in filling bone voids after curettage of benign bone tumors. MATERIALS AND METHODS: Twenty-four patients in the age range of 3.5-55 years (mean 14.3 years) having benign bone tumors with bone defects were filled with bone graft substitute following curettage. In 20 patients bone defects were filled with block/granules of HA ceramic and in four with β-TCP. Fibular strut graft was packed with HA in four patients. The patients were followed up for an average of 18 months (range 12-36 months). RESULTS: The functional status of the patients at follow-up was evaluated and compared with preoperative functional status. Early incorporation of graft substitutes became evident radiologically between 6 and 10 weeks (Stage I). Complete incorporation (Stage III) was observed in an average of nine months (6-18 months). Clinical healing was observed before radiological healing. The average time taken to return to preoperative function was 14 weeks. There was no recurrence of lesion or growth retardation. CONCLUSION: Calcium hydroxyapatite and β-TCP are excellent bone graft substitutes for autogenous bone graft in filling voids after curettage of benign bone tumors.
format Text
id pubmed-2759621
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-27596212009-10-13 Calcium phosphate ceramics as bone graft substitutes in filling bone tumor defects Saikia, KC Bhattacharya, TD Bhuyan, SK Talukdar, DJ Saikia, SP Jitesh, P Indian J Orthop Original Article BACKGROUND: Synthetic bio-inert materials are currently used as an alternative to autogenous bone graft. Calcium hydroxyapatite (HA) and Beta tri-calcium phosphate (β-TCP), which belong to the calcium phosphate ceramics group, are biocompatible and osteo-conductive. The purpose of this study is to analyse the use of HA and β-TCP in their ceramic forms as a bone graft substitute in filling bone voids after curettage of benign bone tumors. MATERIALS AND METHODS: Twenty-four patients in the age range of 3.5-55 years (mean 14.3 years) having benign bone tumors with bone defects were filled with bone graft substitute following curettage. In 20 patients bone defects were filled with block/granules of HA ceramic and in four with β-TCP. Fibular strut graft was packed with HA in four patients. The patients were followed up for an average of 18 months (range 12-36 months). RESULTS: The functional status of the patients at follow-up was evaluated and compared with preoperative functional status. Early incorporation of graft substitutes became evident radiologically between 6 and 10 weeks (Stage I). Complete incorporation (Stage III) was observed in an average of nine months (6-18 months). Clinical healing was observed before radiological healing. The average time taken to return to preoperative function was 14 weeks. There was no recurrence of lesion or growth retardation. CONCLUSION: Calcium hydroxyapatite and β-TCP are excellent bone graft substitutes for autogenous bone graft in filling voids after curettage of benign bone tumors. Medknow Publications 2008 /pmc/articles/PMC2759621/ /pubmed/19826522 http://dx.doi.org/10.4103/0019-5413.39588 Text en © Indian Journal of Psychiatry http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Saikia, KC
Bhattacharya, TD
Bhuyan, SK
Talukdar, DJ
Saikia, SP
Jitesh, P
Calcium phosphate ceramics as bone graft substitutes in filling bone tumor defects
title Calcium phosphate ceramics as bone graft substitutes in filling bone tumor defects
title_full Calcium phosphate ceramics as bone graft substitutes in filling bone tumor defects
title_fullStr Calcium phosphate ceramics as bone graft substitutes in filling bone tumor defects
title_full_unstemmed Calcium phosphate ceramics as bone graft substitutes in filling bone tumor defects
title_short Calcium phosphate ceramics as bone graft substitutes in filling bone tumor defects
title_sort calcium phosphate ceramics as bone graft substitutes in filling bone tumor defects
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759621/
https://www.ncbi.nlm.nih.gov/pubmed/19826522
http://dx.doi.org/10.4103/0019-5413.39588
work_keys_str_mv AT saikiakc calciumphosphateceramicsasbonegraftsubstitutesinfillingbonetumordefects
AT bhattacharyatd calciumphosphateceramicsasbonegraftsubstitutesinfillingbonetumordefects
AT bhuyansk calciumphosphateceramicsasbonegraftsubstitutesinfillingbonetumordefects
AT talukdardj calciumphosphateceramicsasbonegraftsubstitutesinfillingbonetumordefects
AT saikiasp calciumphosphateceramicsasbonegraftsubstitutesinfillingbonetumordefects
AT jiteshp calciumphosphateceramicsasbonegraftsubstitutesinfillingbonetumordefects